NEWSROOM

Medical Research

Aclarion Announces Reverse Stock Split

Aclarion Announces Reverse Stock Split

Mar 26, 2025

BROOMFIELD, Colo., March 26, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (NASDAQ: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Friday March 28, 2025, it will complete a 1-for-27 reverse stock split of its common stock. On September 23, 2024, the Company’s stockholders...

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Mar 24, 2025

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025

IRVINE, Calif., March 18, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration: Register here An archived...

Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects

Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects

Mar 17, 2025

The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award! Key Points: Athena GTX Secures $2.87 Million U.S. Government Contract for Smart Critical Care System Athena GTX has been awarded a $2,866,000 final development contract from the U.S. government for its Smart Autonomous Critical Care System (S-ACCS). This milestone strengthens its position in wireless patient monitoring and life-saving medical technology, with additional government contract awards currently...

Aclarion Provides Shareholder Update

Aclarion Provides Shareholder Update

Mar 13, 2025

Broomfield, CO, March 13, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review. The filing can be viewed here: The Company intends on filing its 10K by the end of March and...

SS Innovations Unveils India’s First Mobile Tele-Surgical Unit at SMRSC 2025

SS Innovations Unveils India’s First Mobile Tele-Surgical Unit at SMRSC 2025

Mar 13, 2025

Fort Lauderdale, FL, March 13, 2025 - PRISM MediaWire - SS Innovations International, Inc. (OTC: SSII) (“SS Innovations” or the “Company”), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable for and accessible to a global population, announced that it unveiled its Mobile Tele-Surgical Unit, aimed at improving remote surgical access and healthcare delivery at the Company’s Second Global Multi-Specialty Robotic Surgery Conference...

SS Innovations Unveils India’s First Mobile Tele-Surgical Unit at SMRSC 2025

SS Innovations International Launches the 2nd Global Robotic Surgery Conference, SMRSC 2025

Mar 7, 2025

Fort Lauderdale, Fla., March 7, 2025 - PRISM MediaWire - SS Innovations International, Inc. (OTC: SSII) (“SS Innovations” or the “Company”), a developer of innovative surgical robotic technologies dedicated to making world-class robotic surgery affordable for and accessible to a global population, announced the launch of its 2nd Global Multi-Specialty Robotic Surgery Conference (SMRSC 2025), organized in collaboration with leading medical societies from both national and international...

Aclarion Announces Reverse Stock Split

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 6, 2025

Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites Broomfield, CO, March 06, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York...

Aclarion Announces Reverse Stock Split

Aclarion Announces First Commercial Agreement with Scripps Health

Mar 3, 2025

Agreement expands access to Nociscan technology for leading spine physicians and more than 3.2M people in the greater San Diego Metro area Nociscan leverages MR Spectroscopy (MRS) and Augmented Intelligence (AI) to Identify Sources of Chronic Low Back Pain Broomfield, CO, March 3, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to...

Aclarion Announces Reverse Stock Split

Aclarion to Showcase Groundbreaking NOCISCAN™ Technology at the 2025 Spine Summit

Feb 20, 2025

Dr. Nicholas Theodore to highlight NOCISCAN capabilities combining MR Spectroscopy and augmented intelligence (AI) NOCISCAN is an innovative decision support tool that helps physicians personalize treatment for chronic low back pain BROOMFIELD, Colo., February 20, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Feb 11, 2025

IRVINE, Calif., Feb. 11, 2025 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to...

Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

Feb 10, 2025

BRIDGEWATER, NJ, February 10, 2025 - PRISM MediaWire - Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its engagement with PCG Advisory, a leading investor relations, strategic communications, and digital strategies firm, to enhance investor outreach and communication efforts. By partnering with PCG...

Aclarion Provides Shareholder Update

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference

Jan 31, 2025

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in Identifying a Source of Discogenic Pain BROOMFIELD, Colo., January 31, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain,...

SS Innovations International Performs World’s First Robotic Cardiac Telesurgeries with its SSi Mantra 3

SS Innovations International Performs World’s First Robotic Cardiac Telesurgeries with its SSi Mantra 3

Jan 13, 2025

A Robotic-Assisted Internal Mammary Artery Harvesting Telesurgery procedure was successfully completed in 58 minutes. The world’s first Robotic Beating Heart Totally Endoscopic Coronary Artery Bypass (TECAB) Telesurgery was performed with a latency of only 40 milliseconds (less than 1/20th of a second). The procedures were performed using the SSi Mantra 3 Surgical Robotic System which was remotely connected from SS Innovations’ headquarters in Gurugram, India to Manipal Hospital in Jaipur,...

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

Jan 13, 2025

POMPANO BEACH, Fla., January 13, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024. 2024 Preliminary Fourth Quarter and Year End Results: Fourth quarter net revenue is expected to...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 8, 2025

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business development efforts and strategic partnerships Irvine, Calif., Jan. 8, 2025 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a...

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Jan 8, 2025

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to evaluate Vendaje® versus...

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

Jan 7, 2025

Published Before-and-After Photos Highlight Dramatic Improvements in Netherton Syndrome Patient Treated with QRX003 New York, January 07, 2024 -PRISM MediaWire - PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) CEO Dr. Michael Myers, who shares the company’s notable interim data in its ongoing Netherton Syndrome clinical trials. Quoin, a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, is addressing unmet...

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24%...

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies CEO to Present at Biotech Showcase 2025

Jan 2, 2025

Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Florida, January 2, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chief Executive Officer, will present a corporate overview and update at the Biotech Showcase 2025 conference, which is...

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Dec 19, 2024

Cardiol Therapeutics President and CEO, David Elsley NEW YORK, December 18, 2024 - PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company’s lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company...